1
|
Marin GH, Murail S, Andrini L, Garcia M, Loisel S, Tuffery P, Rebollo A. In Silico and In Vivo Studies of a Tumor-Penetrating and Interfering Peptide with Antitumoral Effect on Xenograft Models of Breast Cancer. Pharmaceutics 2023; 15:pharmaceutics15041180. [PMID: 37111665 PMCID: PMC10142558 DOI: 10.3390/pharmaceutics15041180] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2023] [Revised: 03/09/2023] [Accepted: 04/05/2023] [Indexed: 04/29/2023] Open
Abstract
The combination of a tumor-penetrating peptide (TPP) with a peptide able to interfere with a given protein-protein interaction (IP) is a promising strategy with potential clinical application. Little is known about the impact of fusing a TPP with an IP, both in terms of internalization and functional effect. Here, we analyze these aspects in the context of breast cancer, targeting PP2A/SET interaction, using both in silico and in vivo approaches. Our results support the fact that state-of-the-art deep learning approaches developed for protein-peptide interaction modeling can reliably identify good candidate poses for the IP-TPP in interaction with the Neuropilin-1 receptor. The association of the IP with the TPP does not seem to affect the ability of the TPP to bind to Neuropilin-1. Molecular simulation results suggest that peptide IP-GG-LinTT1 in a cleaved form interacts with Neuropilin-1 in a more stable manner and has a more helical secondary structure than the cleaved IP-GG-iRGD. Surprisingly, in silico investigations also suggest that the non-cleaved TPPs can bind the Neuropilin-1 in a stable manner. The in vivo results using xenografts models show that both bifunctional peptides resulting from the combination of the IP and either LinTT1 or iRGD are effective against tumoral growth. The peptide iRGD-IP shows the highest stability to serum proteases degradation while having the same antitumoral effect as Lin TT1-IP, which is more sensitive to proteases degradation. Our results support the development of the TPP-IP strategy as therapeutic peptides against cancer.
Collapse
Affiliation(s)
- Gustavo H Marin
- Department of Pharmacology/Histology and Embryology, FMC, National University of La Plata, CONICET, La Plata 1900, Argentina
| | - Samuel Murail
- BFA, Université Paris Cite, CNRS UMR 8251, Inserm U1133, 75013 Paris, France
| | - Laura Andrini
- Department of Pharmacology/Histology and Embryology, FMC, National University of La Plata, CONICET, La Plata 1900, Argentina
| | - Marcela Garcia
- Department of Pharmacology/Histology and Embryology, FMC, National University of La Plata, CONICET, La Plata 1900, Argentina
| | | | - Pierre Tuffery
- BFA, Université Paris Cite, CNRS UMR 8251, Inserm U1133, 75013 Paris, France
| | - Angelita Rebollo
- Faculté de Pharmacie, UTCBS, Université Paris Cite, Inserm U1267, 75006 Paris, France
| |
Collapse
|
2
|
Dorgham K, Murail S, Tuffery P, Savier E, Bravo J, Rebollo A. Binding and Kinetic Analysis of Human Protein Phosphatase PP2A Interactions with Caspase 9 Protein and the Interfering Peptide C9h. Pharmaceutics 2022; 14:pharmaceutics14102055. [PMID: 36297489 PMCID: PMC9609871 DOI: 10.3390/pharmaceutics14102055] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2022] [Revised: 09/22/2022] [Accepted: 09/23/2022] [Indexed: 11/16/2022] Open
Abstract
The serine/threonine phosphatase PP2A and the cysteine protease Caspase 9 are two proteins involved in physiological and pathological processes, including cancer and apoptosis. We previously demonstrated the interaction between Caspase 9 and PP2A and identified the C9h peptide, corresponding to the binding site of Caspase 9 to PP2A. This interfering peptide can modulate Caspase 9/PP2A interaction leading to a strong therapeutic effect in vitro and in vivo in mouse models of tumor progression. In this manuscript, we investigate (I) the peptide binding to PP2A combining docking with molecular dynamics and (II) the secondary structure of the peptide using CD spectroscopy. Additionally, we compare the binding affinity, using biolayer interferometry, of the wild-type protein PP2A with Caspase 9 and vice versa to that observed between the PP2A protein and the interfering peptide C9h. This result strongly encourages the use of peptides as new therapeutics against cancer, as shown for the C9h peptide already in clinical trial.
Collapse
Affiliation(s)
- Karim Dorgham
- Faculty of Medicine, Sorbonne Université, Inserm, CIMI Paris, 91, bd de l’hôpital, 75013 Paris, France
| | - Samuel Murail
- BFA, Université Paris Cité, Inserm 1133, 75013 Paris, France
| | - Pierre Tuffery
- BFA, Université Paris Cité, Inserm 1133, 75013 Paris, France
| | - Eric Savier
- AP-HP, Sorbonne Université, CRSA, 75013 Paris, France
| | - Jeronimo Bravo
- Instituto de Biomedicina de Valencia IBV-CSIC, Jaime Roig, 11, 46010 Valencia, Spain
| | - Angelita Rebollo
- Faculty of Pharmacy, UTCBS, Université Paris Cité, Inserm 1267, 75006 Paris, France
- Correspondence:
| |
Collapse
|